NCT07725796 ICVB-1042 Recurrent Bladder Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07725796 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07725796 is a hot trial to watch
Recurrent Bladder Cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07725796 is notable because it evaluates ICVB-1042 in a Phase 1 design sponsored by UroGen Pharma, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07725796 |
| Official title | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC |
| Phase / status | Phase 1 / Not yet recruiting |
| Intervention | ICVB-1042 |
| Sponsor | UroGen Pharma, Inc. |
| Geography | United States |
| Enrollment | [object Object] |
| Primary endpoint | Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) |
| Endpoint time frame | Up to 15 Months |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).
Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment. Planned enrollment of [object Object] participants across United States shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) (Up to 15 Months) — The number of participants with each type of event will be summarized.
- Concentration of UGN-501 in blood and urine (Up to 12 Weeks) — Data will be summarized using descriptive statistics.
- Complete response rate (CRR) (3 Months) — CRR is defined as the proportion of CIS participants who achieved CR at the Week 12 (3-month) Visit.
- Recurrence-free survival (RFS) rate (6 Months) — RFS rate is defined as the proportion of participants with Ta/T1 disease who are recurrence-free at the 6-month Visit.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: ICVB-1042 is indexed as Oncolytic virus, with target E2F1, mechanism E2F1 modulators, and global highest development status Phase 1.
Company & Deal Intelligence MCP profile: UroGen Pharma, Inc. is resolved to a normalized organization record in MERCER COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07725796 provides a focused lens on Recurrent Bladder Cancer development. Its value will be determined by whether ICVB-1042 can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
